Animal scale-up
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Wajima et al. [63] developed a method for predicting human plasma concentration–time profiles from animal data, building on the earlier Dedrick plot approach [13] but with enhanced flexibility.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [13]
Citations
Cites
Crank, J. (1956) · CERN Document Server (European Organization for Nuclear Research) · Cited by 18,978
Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., & Skipper, H. E. (1966) · PubMed · Cited by 1,382
Ni, W.-M. (2011) · Society for Industrial and Applied Mathematics eBooks · doi:10.1137/1.9781611971972 · Cited by 1,064
Biopharmaceutics and Relevant Pharmacokinetics
Wagne, J. G. (1970) · Drug Information Bulletin · doi:10.1177/009286157000400250 · Cited by 616
ADVANCES IN CHEMISTRY SERIES No. 106
(1972) · Analytical Chemistry · doi:10.1021/ac60318a838 · Cited by 513
Quantitative Relations in the Physiological Constitutions of Mammals
Adolph, E. F. (1949) · Science · doi:10.1126/science.109.2841.579 · Cited by 500 · cited 2×
“Inulin clearance 0.77 PAH clearance 0.80 Basal 0 2 consumption 0.734 Endogenous N output 0.72 O 2 consumption by liver slices 0.77 Kidneys weight 0.85 Heart weight 0.98 Liver weight 0.87 Stomach and intestines weight 0.94 Blood weight 0.99 "Abstracted from Adolph ( 23 ).”
BackgroundInfluentialBischoff, K. B., Dedrick, R. L., Zaharko, D. S., & Longstreth, J. A. (1971) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600600803 · Cited by 480
Self-citationStudies of the enzymatic deamination of cytosine arabinoside—I
Camiener, G. W., & Smith, C. G. (1965) · Biochemical Pharmacology · doi:10.1016/0006-2952(65)90175-9 · Cited by 292
Brodie, B. B., Kurz, H., & Schanker, L. S. (1960) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)25859-1 · Cited by 279
Brodie, B. B., Kurz, H., & Schanker, L. S. (1960) · PubMed · Cited by 255
Research works printed but not linked: 3
- K. B. Bischoff and R. G. Brown. Drug distribution in mammals.Chem. Eng. Prog. Symp. Ser. No. 66 62: 33–45(1966).
- K. B. Bischoff, K. J. Himmelstein, R. L. Dedrick, and D. S. Zaharko. InAdvances in Chemistry Series No. 118, American Chemical Society, Washington, D.C., 1973, pp. 47–64.
- R. L. Dedrick, P. Vantoch, E. A. Gombos, and R. Moore. Kinetics of activated carbon kidney.Trans. Am. Soc. Artif. Int. Organs 13: 236–242 (1967).
Cited by
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
“The methodology was applied to the prediction of plasma concentration–time profiles [3] and the main PK parameters (distribution volumes and clearances) [4], and a number of modifications were subsequently 1.”
MethodDelivery of molecular and cellular medicine to solid tumors
Jain, R. K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.011 · Cited by 774
Transport of Molecules, Particles, and Cells in Solid Tumors
Jain, R. K. (1999) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.1.1.241 · Cited by 691
Strategies to improve plasma half life time of peptide and protein drugs
Werle, M., & Bernkop-Schnürch, A. (2006) · Amino Acids · doi:10.1007/s00726-005-0289-3 · Cited by 660
“To predict renal clearance for humans, the use of inter- species allometric scaling approaches has been quite suc- cessful (Dedrick, 1973; Boxenbaum, 1982; Sawada et al., 1984).”
MethodA physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans
Ramsey, J. C., & Andersen, M. E. (1984) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(84)90064-4 · Cited by 677
Physiologically Based Pharmacokinetic Modeling: Principles and Applications
Gerlowski, L. E., & Jain, R. K. (1983) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600721003 · Cited by 576
Jain, R. K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00131-9 · Cited by 529
Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479
Shah, D. K., & Betts, A. M. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9232-2 · Cited by 422
“PBPK models rely on the same principle of conserved inter-relationships between anatomical, physiological, biochemical and physicochemical processes [11, 35–37] to not only provide quantitative descriptions of the drug disposition process in a biological systems but also to scale drug ADME (absorption, distribution, m…”
A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics
Jones, H. M., Parrott, N., Jorga, K., & Lav??, T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645050-00006 · Cited by 352
“[5,25,45] In contrast, allometric scaling has long been the dominant method for interspecies’ scaling;[2,3,6,7] however, owing to its empirical nature and its failure to account for differences in pharmacokinetics across 0.”
BackgroundMethodDelivery of Molecular Medicine to Solid Tumors
Jain, R. K. (1996) · Science · doi:10.1126/science.271.5252.1079 · Cited by 312
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Jain, R. K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00306-6 · Cited by 298
Deng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S. (2011) · mAbs · doi:10.4161/mabs.3.1.13799 · Cited by 285
Baxter, L. T., Zhu, H. J., Mackensen, D. G., & Jain, R. K. (1994) · PubMed · Cited by 284
Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y., & Sugiyama, Y. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.461 · Cited by 282
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00027-6 · Cited by 271
Ito, K., & Houston, J. B. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9015-1 · Cited by 260
“Blood flow estimates were based on published values for human (28,29) and rat (30,31).”
BackgroundDelivery of Molecular and Cellular Medicine to Solid Tumors
Jain, R. K. (1997) · Microcirculation · doi:10.3109/10739689709148314 · Cited by 198
ALTERNATIVE MODELS FOR DESCRIBING THE BIOCONCENTRATION OF ORGANICS IN FISH
Spacie, A., & Hamelink, J. L. (1982) · Environmental Toxicology and Chemistry · doi:10.1002/etc.5620010406 · Cited by 250
Disposition Characteristics of Macromolecules in Tumor-Bearing Mice
Takakura, Y., Fujita, T., Hashida, M., & Sezaki, H. (1990) · Pharmaceutical Research · doi:10.1023/a:1015807119753 · Cited by 221
Modelling and PBPK Simulation in Drug Discovery
Jones, H. M., Gardner, I. B., & Watson, K. J. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9088-1 · Cited by 202
“Specific reference is made to its utility ( 1 ) at the lead development stage for the prioritization of compounds for animal PK studies and (2) at the clinical candidate selection and “first in human” stages for the prediction of human PK.”
InfluentialRisk Assessment Extrapolations and Physiological Modeling
M.A., H. J. C. I., & Andersen, M. E. (1985) · Toxicology and Industrial Health · doi:10.1177/074823378500100408 · Cited by 213
Delivery of molecular and cellular medicine to solid tumors
Jain, R. K. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00237-x · Cited by 186
Clewell, R. A., & Clewell, H. J. (2008) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2007.10.012 · Cited by 173
“If any of the listed parameter values are based on allometric scaling (Dedrick, 1973; Dedrick and Bischoff, 1980; EPA, 1992), a footnote should provide the body weight used to obtain the allometric constant as well as the power of body weight used in the scaling.”
BackgroundBaxter, L. T., Zhu, H. J., Mackensen, D. G., Butler, W. F., & Jain, R. K. (1995) · PubMed · Cited by 180
Toxicokinetic modeling and its applications in chemical risk assessment
Andersen, M. E. (2003) · Toxicology Letters · doi:10.1016/s0378-4274(02)00375-2 · Cited by 173
“…modeling process referred to as physiologically based pharmacokinetic (PBPK) modeling is particularly well-suited to calculation of tissue doses of chemicals and their metabolites over a wide range of exposure conditions in different species (Dedrick, 1973; Clewell and Andersen, 1985; Leung, 1991).”
MethodCornfield, J. (1977) · Science · doi:10.1126/science.910152 · Cited by 172
Dong, J. Q., Salinger, D. H., Endres, C. J., Gibbs, J. P., Hsu, C.-P., Stouch, B. J., Hurh, E., & Gibbs, M. A. (2011) · Clinical Pharmacokinetics · doi:10.2165/11537430-000000000-00000 · Cited by 156
“For the ten mAbs (four marketed mAbs and six proprietary mAbs [mAbs a to f]) exhibiting linear pharmacokinetics in monkeys, principles of allometric scaling([29,30]) were applied to scale CL and Vd from monkeys to humans.”
MethodBiological basis for extrapolation across mammalian species
Davidson, I. W. F., Parker, J. C., & Beliles, R. P. (1986) · Regulatory Toxicology and Pharmacology · doi:10.1016/0273-2300(86)90014-0 · Cited by 158
Interspecies scaling and comparisons in drug development and toxicokinetics
Ings, R. M. J. (1990) · Xenobiotica · doi:10.3109/00498259009046839 · Cited by 151
Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans
Mager, D. E., Woo, S., & Jusko, W. J. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.16 · Cited by 141
Methods for Vascular Access and Collection of Body Fluids from the Laboratory Rat
Cocchetto, D. M., & Bjornsson, T. D. (1983) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600720503 · Cited by 145
Ferl, G. Z., Wu, A. M., & DiStefano, J. J. (2005) · Annals of Biomedical Engineering · doi:10.1007/s10439-005-7410-3 · Cited by 150
Physiologically based pharmacokinetics (PBPK)
Espié, P., Tytgat, D., Sargentini-Maier, M.-L., Poggesi, I., & Watelet, J.-B. (2009) · Drug Metabolism Reviews · doi:10.1080/10837450902891360 · Cited by 136
“The empirical allometric scaling of pharmacokinetic parameters is based on Equation 1, assuming that there are anatomical, physiological, and biochemical similarities among animals (Dedrick, 1973; Mordenti, 1986).”
BackgroundAndersen, M. E. (1981) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(81)90338-0 · Cited by 139
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.
Goldsmith, M. A., Slavik, M., & Carter, S. K. (1975) · PubMed · Cited by 134
Kanamitsu, S.-I., Ito, K., & Sugiyama, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007509324428 · Cited by 130
Fate of Water‐Soluble Polymers Administered via Different Routes
Yamaoka, T., Tabata, Y., & Ikada, Y. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600840316 · Cited by 130
Development of Translational Pharmacokinetic–Pharmacodynamic Models
Mager, D., & Jusko, W. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.52 · Cited by 124
Deng, R., Jin, F., Prabhu, S., & Iyer, S. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.643868 · Cited by 126
Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs
Takakura, Y., & Hashida, M. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00131-c · Cited by 122
Thiel, C., Schneckener, S., Krauß, M., Ghallab, A., Hofmann, U., Kanacher, T., Zellmer, S., Gebhardt, R., Hengstler, J. G., & Kuepfer, L. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24214 · Cited by 129
Estimation of tissue-to-plasma partition coefficients used in physiological pharmacokinetic models
Chen, H.-S. G., & Gross, J. F. (1979) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059446 · Cited by 119
“Successful use of this approach for scale-up from animals to humans has been demonstrated by Dedrick ( 15 ).”
BackgroundPrediction of pharmacokinetic properties using experimental approaches during early drug discovery
Chaturvedi, P. R., Decker, C. J., & Odinecs, A. (2001) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00228-3 · Cited by 133
Prediction of the volumes of distribution of basic drugs in humans based on data from animals
Sawada, Y., Hanano, M., Sugiyama, Y., Harashima, H., & Iga, T. (1984) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059554 · Cited by 117
“The linear regression of the logarithmic values was calculated by the least squares method to give the parameters in the power law formula: y = A" x ~ (3) where y is the ordinate and x is the abscissa.”
BackgroundMethodSawada, Y., Hanano, M., Sugiyama, Y., & Iga, T. (1984) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061720 · Cited by 123
“This has certainly been the case in the past ( 1-6 ).”
BackgroundDiscovery and development of new antimicrobial agents
Gootz, T. D. (1990) · Clinical Microbiology Reviews · doi:10.1128/cmr.3.1.13 · Cited by 131
Pharmacokinetic modeling in aquatic animals I. Models and concepts
Barron, M. G., Stehly, G. R., & Hayton, W. L. (1990) · Aquatic Toxicology · doi:10.1016/0166-445x(90)90063-u · Cited by 113
The Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I Protocols
Mahmood, I., & Balian, J. D. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936010-00001 · Cited by 112
Jones, H. M., Gardner, I. B., Collard, W. T., Stanley, P. J., Oxley, P., Hosea, N. A., Plowchalk, D., Gernhardt, S., Lin, J., Dickins, M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539680-000000000-00000 · Cited by 110
A Unified Probabilistic Framework for Dose–Response Assessment of Human Health Effects
Chiu, W. A., & Slob, W. (2015) · Environmental Health Perspectives · doi:10.1289/ehp.1409385 · Cited by 109
“Dedrick RL. 1973.”
Lombardo, F., Waters, N. J., Argikar, U. A., Dennehy, M. K., Zhan, J., Gunduz, M., Harriman, S. P., Berellini, G., Liric Rajlic, I., & Obach, R. S. (2013) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012440282 · Cited by 106
“For clearance, methods such as scaling from in vitro human tissue or in vitro animal and human tissue, in vivo interspecies scaling, physiologically based pharmacokinetic (PK) modeling, and Dedrick analysis have been used.(1) Methods employing scaled intrinsic clearance measured in an in vitro cellular or subcellular…”
MethodMahmood, I., & Balian, J. D. (1996) · Journal of Pharmaceutical Sciences · doi:10.1021/js950400y · Cited by 105
Igari, Y., Sugiyama, Y., Sawada, Y., Iga, T., & Hanano, M. (1983) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059058 · Cited by 105
“Furthermore, under certain conditions, physiologically based pharmacokinetic models can be scaled to more than one species ( 4 ).”
BackgroundPhysiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibody
Urva, S., Yang, V. C.-M., & Balthasar, J. P. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21918 · Cited by 108
“The PBPK model would allow mechanistic investigation of known or suspected determinants of interindividual pharmacokinetic variability, perhaps including the ‘‘body load’’ of tumor, the extent of antigen expression on tumor tissue and on healthy tissue, vascular permeability, tumor blood flow, and rates of lymph flow.…”
Pharmacokinetic modeling in aquatic animals I. Models and concepts
Barron, M. G., Stehly, G. R., & Hayton, W. L. (1990) · Aquatic Toxicology · doi:10.1016/0166-445x(90)90019-l · Cited by 103
Di, L., Feng, B., Goosen, T. C., Lai, Y., Steyn, S. J., Varma, M. V. S., & Obach, R. S. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.054031 · Cited by 107
“However, it is interesting to note that allometry worked well for prediction of the CLr of creatinine and fluconazole, which involve tubular secretion in humans (Dedrick, 1973; Jezequel, 1994).”
BackgroundExtravascular transport in normal and tumor tissues
Jain, R. K., Gerlowski, L. E., & Cilento, E. V. (1986) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(86)80023-3 · Cited by 103
Body distribution profile of polysaccharides after intravenous administration
Yamaoka, T., Tabata, Y., & Ikada, Y. (1993) · Drug Delivery · doi:10.3109/10717549309031345 · Cited by 98
Concepts and Issues with Interspecies Scaling in Zoological Pharmacology
Hunter, R. P., & Isaza, R. (2008) · Journal of Zoo and Wildlife Medicine · doi:10.1638/2008-0041.1 · Cited by 99
Saturable Metabolism and its Relationship to Toxicity
Andersen, M. E., & McKenna, M. J. (1981) · Critical Reviews in Toxicology · doi:10.3109/10408448109059563 · Cited by 98
Holleran, J. L., Parise, R. A., Joseph, E., Eiseman, J. L., Covey, J. M., Glaze, E. R., Lyubimov, A. V., Chen, Y.-F., D’Argenio, D. Z., & Egorin, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2406 · Cited by 97
“studies of zebularine used standard methods ( 14 ).”
MethodNagilla, R., & Ward, K. W. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20169 · Cited by 96
A physiologically based pharmacokinetic model for inhaled carbon tetrachloride
Paustenbach, D. J., M.A., H. J. C. I., Gargas, M. L., & Andersen, M. E. (1988) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(88)90080-4 · Cited by 95
Pharmacokinetic concepts ? Drug binding, apparent volume of distribution and clearance
Gibaldi, M., & Koup, J. R. (1981) · European Journal of Clinical Pharmacology · doi:10.1007/bf00618781 · Cited by 95
“Most reports concerning blood flow rate-limited physiologically-based pharmacokinetic models (Dedrick 1973; Bischoff 1975; Anderson et al. 1977; Dedrick and Bischoff 1980) have expressed this term as CIICL/RL; this condition prevails when either fB = 1 or the rate of drug elimination is a function of total drug concen…”
BackgroundAndersen, M. E. (1995) · Toxicology Letters · doi:10.1016/0378-4274(95)03355-o · Cited by 94
Wada, D., Björkman, S. E., Ebling, W. F., Harashima, H., Harapat, S. R., & Stanski, D. R. (1997) · Anesthesiology · doi:10.1097/00000542-199710000-00024 · Cited by 93
Allometric issues in drug development†
Mahmood, I. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js9902163 · Cited by 91
Lin, J. H., Sugiyama, Y., Awazu, S., & Hanano, M. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062546 · Cited by 91
“The aim of the present study was thus to predict the time course of EB concentrations in plasma and various tissues of the rat without use of any in vivo data and to scale up such a prediction from the rat to the rabbit ( 7 ,8).”
BackgroundEl-Kareh, A. W., & Secomb, T. W. (2004) · Neoplasia · doi:10.1593/neo.03205 · Cited by 89
“Based on the findings of Dedrick [9] that the half-life of methotrexate showed only weak dependence on body weight (slope 0.”
BackgroundInfluentialGlassman, P. M., & Balthasar, J. P. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9482-0 · Cited by 93
“, 70 kg for man), and b is the scaling exponent [10].”
Tsukamoto, Y., Kato, Y., Ura, M., Horii, I., Ishitsuka, H., Kusuhara, H., & Sugiyama, Y. (2001) · Pharmaceutical Research · doi:10.1023/a:1010939329562 · Cited by 89
“dC4n dt = 5 × C1n + a(n−1) × Vmax4(n−1) × fB(n−1) × V4 Km4(n−1) + fB(n−1) × C4(n−1) Kp4(n−1) × C4(n−1) Kp4(n−1) − 1 + an × Vmax4n × fBn × V4 Km4n + fBn × C4n Kp4 2 × C4n Kp4n6 /V4 (9)”
MethodPharmacokinetic Scale-up: Accurate Prediction of Human Pharmacokinetic Profiles from Animal Data
Mordenti, J. J. (1985) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600741017 · Cited by 87
Sawada, Y., Hanano, M., Sugiyama, Y., & Iga, T. (1985) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059331 · Cited by 97
“(1) DPH, (2) HEB, (3) PEB, (4) PBZ, (5) WA, (6) TB, (7) VA, (8) PB, (9) AMB, (10) QD, (11) CPZ, (12) PL, (13) PTZ, (14) DZP, and (15) AP.”
BackgroundInfluentialIn silico and in vitro pharmacogenetics: aldehyde oxidase rapidly metabolizes a p38 kinase inhibitor
Zhang, X., Liu, H.-H., Weller, P. E., Zheng, M., Tao, W., Wang, J., Liao, G., Monshouwer, M., & Peltz, G. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.8 · Cited by 91
Gargas, M. L., Seybold, P. G., & Andersen, M. E. (1988) · Toxicology Letters · doi:10.1016/0378-4274(88)90031-8 · Cited by 83
Lowe, P. J., Hijazi, Y., Luttringer, O., Yin, H., Sarangapani, R., & Howard, D. (2007) · Xenobiotica · doi:10.1080/00498250701648008 · Cited by 81
1995 Whitaker lecture: Delivery of molecules, particles, and cells to solid tumors
Jain, R. K. (1996) · Annals of Biomedical Engineering · doi:10.1007/bf02648108 · Cited by 80
Physiologic pharmacokinetic models and interanimal species scaling
Rowland, M. (1985) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(85)90016-6 · Cited by 84
Choi, G.-W., Lee, Y.-B., & Cho, H.-Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040168 · Cited by 79
“The allometric equation is generally expressed as a power function based on the following equation [20]: Y = aWb (73)”
MethodAnimal models in the evaluation of antimicrobial agents
Zak, O., & O'Reilly, T. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.8.1527 · Cited by 79
Prediction of human pharmacokinetics — renal metabolic and excretion clearance
Fagerholm, U. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.11.0002 · Cited by 76
“Evaluation of methods for predicting renal clearance Allometry for prediction of renal excretion clearance In some cases, such as for creatinine and fluconazole, allometry has worked well for prediction of the excretion CLR in humans (Dedrick 1973; Jezequel 1994).”
MethodKleinow, K. M., Nichols, J. W., Hayton, W. L., McKim, J. M., & Barron, M. G. (2008) · CRC Press eBooks · doi:10.1201/9780203647295.ch3 · Cited by 78
Comparative pharmacokinetics of benzodiazepines in dog and man
Boxenbaum, H. G. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01065172 · Cited by 84
“More recently, a number of different approaches have been tried with good success (7,9,11,15-17,19-22).”
BackgroundFagerholm, U. (2007) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.59.6.0007 · Cited by 76
“The data collected by those authors demonstrated that 80–90% of compounds that were predicted (from animal data) to have low CL in man experimentally demonstrated low CL. Correct CL classification for drugs with moderate and high CL was lower, approximately 20–30% and 30–50%, respectively.”
BackgroundInfluentialNishimuta, H., Nakagawa, T., Nomura, N., & Yabuki, M. (2013) · Xenobiotica · doi:10.3109/00498254.2013.787155 · Cited by 81
“Over the past few decades, several approaches have been developed for providing quantitative predictions of human pharmacokinetics (Dedrick, 1973; Houston, 1994; Iwatsubo et al., 1997; Mordenti, 1986).”
BackgroundPharmacokinetics of tetrachloroethylene*1
Ward, R. C. (1988) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(88)90030-0 · Cited by 76
Westerhout, J., Danhof, M., & de Lange, E. C. M. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22604 · Cited by 79
Komatsu, K., Ito, K., Nakajima, Y., Kanamitsu, S.-I., Imaoka, S., Funae, Y., Green, C. E., Tyson, C. A., Shimada, N., & Sugiyama, Y. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15066-0 · Cited by 74
Pharmacokinetic model based on circulatory transport
Weiss, M., & F�rster, W. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00608408 · Cited by 72
Woo, S., & Jusko, W. J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015248 · Cited by 72
“Despite nonlinear rHuEPO disposition, CL and Vss were highly correlated with body weight (R 2 > 0.92) with allometric scaling exponents of 0.708 for CL and 0.853 for Vss.”
BackgroundInfluentialMechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats
Kato, M., Kamiyama, H., Okazaki, A., Kumaki, K., Kato, Y., & Sugiyama, Y. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37074-0 · Cited by 72
Clewell, R. A., Kremer, J. J., Williams, C. C., Campbell, J. L., Andersen, M. E., & Borghoff, S. J. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn054 · Cited by 75
“Therefore kinetic parameters were kept the same for both strains and scaled allometrically as is typical for intra- and interspecies extrapolation (Dedrick, 1973).”
MethodCarcinogenic Risk Assessment: A Guide to the Literature
Krewski, D. R., & Brown, C. (1981) · Biometrics · doi:10.2307/2530423 · Cited by 71
Iwatsubo, T., Suzuki, H., & Sugiyama, Y. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37073-9 · Cited by 69
Baxter, L. T., Yuan, F., & Jain, R. K. (1992) · PubMed · Cited by 70
Wang, J., Iyer, S., Fielder, P. J., Davis, J. D., & Deng, R. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1952 · Cited by 69
Interspecies extrapolation of pharmacokinetics
Travis, C. C., White, R. K., & Ward, R. C. (1990) · Journal of Theoretical Biology · doi:10.1016/s0022-5193(05)80554-5 · Cited by 72
Harrison, L. I., & Gibaldi, M. (1977) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600661206 · Cited by 67
Metadata
- Authors
- Dedrick, R. L.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Dedrick, Robert L.
- Venue
- Journal of Pharmacokinetics and Biopharmaceutics
- Published
- 1973-10
- Volume
- 1
- Issue
- 5
- Pages
- 435-461
- ISSN
- 0090-466X (ISSN-L)
- OpenAlex
- W2042365192
- Cited by
- 397
- References
- 52
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 6 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 11 · 2018: 7 · 2017: 2 · 2016: 8 · 2015: 6 · 2014: 5 · 2013: 15 · 2012: 14
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Pharmacokinetics and Biopharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- drug distribution, blood flow, tissue binding, renal clearance, drug metabolism, species differences, methotrexate, thiopental, cytarabine
- MeSH terms
- Animals, Biological Transport, Biotransformation, Body Weight, Chlorides, Cytarabine, Dialysis, Diffusion, Pharmaceutical Preparations, Humans, Kinetics, Mammals, Methotrexate, Models, Biological, Organ Specificity, Pharmacology, Species Specificity, Thermodynamics, Thiopental, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.